Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study - Summary - MDSpire

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • By

  • Zimu Gong

  • Godsfavour Umoru

  • Jorge Monge

  • Nishi Shah

  • Ghulam Rehman Mohyuddin

  • Sabarinath Venniyil Radhakrishnan

  • Rajshekhar Chakraborty

  • Leo Rasche

  • Carolina Schinke

  • Anita D’Souza

  • Meera Mohan

  • March 5, 2024

  • 0 min

Share

Objective:

To analyze the adverse effects and non-relapse mortality (NRM) associated with FDA-approved BCMA-directed T cell therapies in multiple myeloma.

Key Findings:
  • Teclistamab had the highest rates of life-threatening events (11.3%) and death (22.1%) compared to ide-cel and cilta-cel.
  • Cytokine release syndrome (CRS) was most common with ide-cel (16.1%), while infections were more prevalent with teclistamab.
  • Teclistamab exhibited the highest OR for NRM (1.72), while ide-cel had the lowest (0.53).
Interpretation:

The study highlights distinct toxicity profiles among BCMA-directed therapies, with teclistamab showing higher rates of severe adverse effects and NRM, potentially linked to its patient population and infection-related complications, which underscores the need for careful patient selection and monitoring.

Limitations:
  • The analysis is based on voluntarily reported data, which may lead to underreporting or bias.
  • Elranatamab was excluded due to insufficient cases, limiting the comprehensiveness of the findings.
Conclusion:

BCMA-directed T cell therapies demonstrate varying toxicity profiles, with teclistamab associated with higher morbidity and mortality, emphasizing the need for careful patient selection and monitoring.

Original Source(s)

Adverse effects and non-relapse mortality of BCMA directed T cell therapies in multiple myeloma: an FAERS database study

  • by Zimu Gong, Godsfavour Umoru, Jorge Monge, Nishi Shah, Ghulam Rehman Mohyuddin, Sabarinath Venniyil Radhakrishnan, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D’Souza, Meera Mohan

  • March 5, 2024

Related Content

Exploring the Therapeutic Promise of γδ T Cells in Blood Disorders: Bridging Immunobiology and Clinical Innovation

Not all plasma cells are made equal: well-hidden layers of heterogeneity

Prognostic Impact of Early Disease Progression and Early Mortality in Patients with Multiple Myeloma: A Real-World Cohort Study